STOCK TITAN

Patterson Companies Reports Fiscal 2025 First Quarter Operating Results

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

Patterson Companies (Nasdaq: PDCO) reported fiscal 2025 first quarter results with net sales decreasing 2.2% year-over-year to $1.54 billion. The company faced challenges due to the cybersecurity attack on Change Healthcare, impacting its dental segment's value-added services. GAAP earnings were $0.15 per diluted share, while adjusted earnings were $0.24 per diluted share. Despite these setbacks, Patterson reaffirmed its fiscal 2025 guidance, projecting GAAP earnings of $2.00 to $2.10 per diluted share and adjusted earnings of $2.33 to $2.43 per diluted share. The company returned $73.3 million to shareholders through dividends and share repurchases in Q1.

Patterson Companies (Nasdaq: PDCO) ha riportato i risultati del primo trimestre fiscale 2025, con vendite nette in calo del 2,2% rispetto all'anno precedente, arrivando a 1,54 miliardi di dollari. L'azienda ha affrontato delle difficoltà a causa del cyber attacco a Change Healthcare, che ha impattato i servizi a valore aggiunto del suo segmento dentale. Gli utili GAAP sono stati di 0,15 dollari per azione diluita, mentre gli utili rettificati sono stati di 0,24 dollari per azione diluita. Nonostante questi ostacoli, Patterson ha confermato le sue previsioni per il fiscale 2025, proiettando utili GAAP compresi tra 2,00 e 2,10 dollari per azione diluita e utili rettificati compresi tra 2,33 e 2,43 dollari per azione diluita. L'azienda ha restituito 73,3 milioni di dollari agli azionisti attraverso dividendi e riacquisti di azioni nel primo trimestre.

Patterson Companies (Nasdaq: PDCO) informó sobre los resultados del primer trimestre fiscal 2025, con ventas netas que disminuyeron un 2.2% interanual, alcanzando 1.54 mil millones de dólares. La empresa enfrentó desafíos debido al ataque cibernético a Change Healthcare, afectando los servicios de valor agregado de su segmento dental. Las ganancias GAAP fueron de 0.15 dólares por acción diluida, mientras que las ganancias ajustadas fueron de 0.24 dólares por acción diluida. A pesar de estos contratiempos, Patterson reafirmó su guía fiscal 2025, proyectando ganancias GAAP de 2.00 a 2.10 dólares por acción diluida y ganancias ajustadas de 2.33 a 2.43 dólares por acción diluida. La empresa devolvió 73.3 millones de dólares a los accionistas a través de dividendos y recompra de acciones en el primer trimestre.

패터슨 컴퍼니(Patterson Companies, Nasdaq: PDCO)는 2025 회계연도 1분기 실적을 발표했으며, 순매출이 전년 대비 2.2% 감소하여 15억 4천만 달러에 이르렀습니다. 회사는 Change Healthcare에 대한 사이버 공격으로 인해 치과 부문의 부가가치 서비스에 영향을 받으며 어려움을 겪었습니다. GAAP 기준의 주당 희석 이익은 0.15달러, 조정 후 이익은 0.24달러였습니다. 이러한 어려움에도 불구하고 패터슨은 2025 회계연도 가이던스를 재확인하며 주당 GAAP 이익을 2.00~2.10달러, 조정 후 이익을 2.33~2.43달러로 예측했습니다. 이 회사는 1분기 동안 배당금과 자사주 매입을 통해 7천 3백 30만 달러를 주주에게 환원했습니다.

Patterson Companies (Nasdaq: PDCO) a annoncé ses résultats du premier trimestre fiscal 2025, avec des ventes nettes en baisse de 2,2 % par rapport à l'année précédente, s'élevant à 1,54 milliard de dollars. L'entreprise a été confrontée à des défis en raison de l'attaque informatique sur Change Healthcare, impactant les services à valeur ajoutée de son segment dentaire. Les bénéfices GAAP étaient de 0,15 dollar par action diluée, tandis que les bénéfices ajustés étaient de 0,24 dollar par action diluée. Malgré ces revers, Patterson a réaffirmé ses prévisions pour le fiscal 2025, projetant des bénéfices GAAP compris entre 2,00 et 2,10 dollars par action diluée et des bénéfices ajustés compris entre 2,33 et 2,43 dollars par action diluée. L'entreprise a retourné 73,3 millions de dollars aux actionnaires par le biais de dividendes et de rachats d'actions au premier trimestre.

Patterson Companies (Nasdaq: PDCO) berichtete über die Ergebnisse des ersten Quartals des Geschäftsjahres 2025, wobei die Nettoumsätze im Jahresvergleich um 2,2% auf 1,54 Milliarden Dollar zurückgingen. Das Unternehmen sah sich aufgrund des Cyberangriffs auf Change Healthcare mit Herausforderungen konfrontiert, die die wertschöpfenden Dienstleistungen seines zahnärztlichen Segments beeinträchtigten. Die GAAP-Gewinne betrugen 0,15 Dollar pro verwässerter Aktie, während die angepassten Gewinne 0,24 Dollar pro verwässerter Aktie betrugen. Trotz dieser Rückschläge bestätigte Patterson seine Prognose für das Geschäftsjahr 2025, mit einer Prognose für GAAP-Gewinne zwischen 2,00 und 2,10 Dollar pro verwässerter Aktie sowie angepassten Gewinnen zwischen 2,33 und 2,43 Dollar pro verwässerter Aktie. Das Unternehmen gab 73,3 Millionen Dollar an die Aktionäre zurück durch Dividenden und Aktienrückkäufe im ersten Quartal.

Positive
  • Reaffirmed fiscal 2025 earnings guidance
  • Returned $73.3 million to shareholders through dividends and share repurchases
  • Free cash flow improved by $1.8 million compared to Q1 fiscal 2024
  • Value-added services in Animal Health segment increased 8.3%
Negative
  • Net sales decreased 2.2% year-over-year to $1.54 billion
  • Internal sales decreased 2.8% compared to the previous year
  • GAAP earnings decreased to $0.15 per diluted share from $0.32 in Q1 fiscal 2024
  • Adjusted earnings decreased to $0.24 per diluted share from $0.40 in Q1 fiscal 2024
  • Dental segment internal sales decreased 2.8%
  • Animal Health segment internal sales declined 2.8%

Insights

Patterson Companies' Q1 FY2025 results show concerning trends. Net sales decreased by 2.2% year-over-year to $1.54 billion, with internal sales down 2.8%. The GAAP earnings per diluted share fell to $0.15 from $0.32 in the previous year, while adjusted earnings dropped to $0.24 per share from $0.40.

The cybersecurity attack on Change Healthcare significantly impacted the dental segment's value-added services. Both the dental and animal health segments experienced declines, with internal sales decreasing 2.8% in each. Despite these challenges, the company returned $73.3 million to shareholders through dividends and share repurchases.

While Patterson reaffirmed its FY2025 guidance, the Q1 performance raises concerns about achieving these targets. Investors should closely monitor the company's cost management initiatives and their ability to navigate the challenging macroeconomic environment.

The dental and animal health markets are showing signs of weakness, as reflected in Patterson's Q1 results. The dental segment's internal sales declined across all categories, with consumables down 2.1%, equipment down 2.4% and value-added services plummeting 6.7%. Similarly, the animal health segment saw declines in consumables (3.0%) and equipment (3.8%), though value-added services grew 8.3%.

These results suggest a broader slowdown in both markets, possibly due to economic pressures affecting consumer spending on dental care and pet services. The cybersecurity attack on Change Healthcare adds another layer of complexity, disrupting the dental segment's performance. Investors should watch for industry-wide trends and competitor performance to gauge whether Patterson's challenges are company-specific or indicative of larger market shifts.

The cybersecurity attack on Change Healthcare has had a significant negative impact on Patterson's dental segment, particularly in value-added services. This incident highlights the growing importance of cybersecurity in healthcare and related industries. As digital transformation accelerates in these sectors, companies become increasingly vulnerable to such attacks.

Patterson's experience underscores the need for robust cybersecurity measures and contingency plans. The prolonged impact of this attack on financial performance suggests that recovery from such incidents can be complex and time-consuming. Investors should consider the cybersecurity preparedness of companies in their portfolio, as such incidents can have material financial consequences.

Moving forward, Patterson may need to invest in strengthening its digital infrastructure and that of its partners to prevent similar disruptions. This could lead to increased IT expenditures in the short term but may be necessary for long-term resilience and competitiveness.

  • First quarter reported net sales decreased 2.2 percent year-over-year to $1.54 billion, and internal sales decreased 2.8 percent.
  • Returned $73.3 million to shareholders in first quarter of fiscal 2025 through dividends and share repurchases.
  • Delivered first quarter GAAP earnings of $0.15 per diluted share and adjusted earnings1 of $0.24 per diluted share; both GAAP and adjusted earnings1 were negatively impacted by the cybersecurity attack on Change Healthcare compared to the prior year.
  • Reaffirms fiscal 2025 GAAP earnings guidance range of $2.00 to $2.10 per diluted share and adjusted earnings1 guidance range of $2.33 to $2.43 per diluted share.

ST. PAUL, Minn.--(BUSINESS WIRE)-- Patterson Companies, Inc. (Nasdaq: PDCO) today reported operating results for its fiscal 2025 first quarter ended July 27, 2024.

"Our first quarter results fell short of our expectations, primarily due to the greater than anticipated impact of the Change Healthcare cybersecurity attack on the value-added services category in our dental segment, along with lower sales in our companion animal business and the timing of certain corporate expenses," said Don Zurbay, President and CEO of Patterson Companies. "In light of these factors and against the backdrop of a challenging macroeconomic environment, we are taking dedicated cost and management actions across Patterson to deliver on our financial plan for fiscal 2025, and maintaining a strategic focus on supporting our customers with the deep and differentiated value-proposition they expect from us."

First Quarter Fiscal 2025 Results

Consolidated net sales were $1.54 billion (see attached Sales Summary for further details), a decrease of 2.2 percent compared to the same period last year. Internal sales, which are adjusted for the effects of currency translation and the net impact of an interest rate swap, decreased 2.8 percent over the prior year period.

Reported net income attributable to Patterson Companies, Inc. for the first quarter of fiscal 2025 was $13.7 million, or $0.15 per diluted share, compared to $31.2 million, or $0.32 per diluted share, in the first quarter of fiscal 2024. Adjusted net income1 attributable to Patterson Companies, Inc., which excludes deal amortization totaled $21.0 million for the first quarter of fiscal 2025, or $0.24 per diluted share, compared to $38.6 million, or $0.40 per diluted share, in the first quarter of fiscal 2024. The year-over-year decrease in reported and adjusted net income attributable to Patterson Companies, Inc. in the first quarter of fiscal 2025 is related to lower retail sales and operating margins in both business segments and the continued negative impact of the widely reported cybersecurity attack on vendor Change Healthcare, within the value-added services category of the dental segment. Both reported and adjusted net income in the fiscal 2025 first quarter were negatively impacted by the cybersecurity attack on Change Healthcare compared to the prior year period.

Patterson Dental

Reported net sales in the Dental segment for the first quarter of fiscal 2025 were $550.4 million. Internal sales decreased 2.8 percent compared to the fiscal 2024 first quarter. Internal sales of consumables decreased 2.1 percent year-over-year. Excluding the deflationary impact of certain infection control products, internal sales of consumables decreased 1.7 percent year-over-year. Compared to the prior year period, internal sales of equipment decreased 2.4 percent. Internal sales of value-added services decreased 6.7 percent compared to the prior year period, primarily due to the negative impact of the cybersecurity attack on Change Healthcare.

Patterson Animal Health

Reported net sales in the Animal Health segment for the first quarter of fiscal 2025 were $982.4 million. Internal sales declined 2.8 percent compared to the fiscal 2024 first quarter. Compared to the prior year period, internal sales of consumables declined 3.0 percent, equipment decreased 3.8 percent and value-added services increased 8.3 percent.

Balance Sheet and Capital Allocation

During the first quarter of fiscal 2025, Patterson Companies used $285.0 million of cash from operating activities and collected deferred purchase price receivables of $271.8 million, using $13.1 million in cash, compared to using $11.4 million during the first quarter of fiscal 2024. Free cash flow1 (see definition below and attached free cash flow table) during the first quarter of fiscal 2025 improved by $1.8 million compared to the first quarter of fiscal 2024.

In the first quarter of fiscal 2025, Patterson Companies declared a quarterly cash dividend of $0.26 per share, returning $23.3 million in cash dividends to shareholders. Also, under a prior repurchase authorization, the company repurchased approximately $50.0 million of shares during the fiscal first quarter. At of the end of the first quarter of fiscal 2025, Patterson had approximately $450 million of share repurchase authority remaining on its current share repurchase authorization. During the first quarter of fiscal 2025, Patterson Companies returned $73.3 million to shareholders in the form of cash dividends and share repurchases.

Fiscal 2025 Guidance

Patterson Companies today reaffirmed its fiscal 2025 earnings guidance, which is provided on both a GAAP and non-GAAP adjusted1 basis:

  • GAAP earnings are expected to be in the range of $2.00 to $2.10 per diluted share.
  • Non-GAAP adjusted earnings1 are expected to be in the range of $2.33 to $2.43 per diluted share.
  • Our non-GAAP adjusted earnings1 guidance excludes the after-tax impact of:
    • Deal amortization expenses of approximately $29.1 million ($0.33 per diluted share).

Our guidance reflects the strength of our business and competitive positioning as well as completed and previously announced acquisitions. It does not include the impact of unplanned share repurchases, potential future acquisitions or similar transactions, impairments, restructuring and integration expenses not previously publicly disclosed, or amortization expense of acquired intangible assets. Our guidance assumes North American and international end market conditions consistent with current market conditions.

1Non-GAAP Financial Measures

The term “internal sales” used in this release represents net sales adjusted for the effects of currency translation and the net impact of an interest rate swap. Foreign currency impact represents the difference in results that is attributable to fluctuations in currency exchange rates the company uses to convert results for all foreign entities where the functional currency is not the U.S. dollar. The company calculates the impact as the difference between the current period results translated using the current period currency exchange rates and using the comparable prior period’s currency exchange rates. The company believes the disclosure of net sales excluding the impact of foreign currency and an interest rate swap provides useful supplementary information to investors in light of fluctuations in these variables that are independent of our period-over-period performance.

The term “free cash flow” used in this release is defined as net cash used in operating activities less capital expenditures plus the collection of deferred purchase price receivables.

The Reconciliation of GAAP to non-GAAP Measures table appearing behind the accompanying financial information is provided to adjust reported GAAP measures, namely net sales, gross profit, operating expenses, operating income, other income (expense), net, income before taxes, income tax expense, net income, net loss attributable to noncontrolling interests, net income attributable to Patterson Companies, Inc., and diluted earnings per share attributable to Patterson Companies, Inc. for the impact of deal amortization and an interest rate swap along with any related tax effects of these items.

  • Deal amortization represents non-cash intangible amortization expense, primarily related to the acquisition of Animal Health International.
  • Interest rate swap -- Our customer financing net sales include the impact of changes in interest rates on deferred purchase price receivables, as the average interest rate in our contract portfolio may not fluctuate at the same rate as interest rate markets, resulting in an increase or reduction of gain on contract sales.

    We enter into an interest rate swap to hedge a portion of the related interest rate risk. These agreements do not qualify for hedge accounting, and the gains or losses on an interest rate swap are reported in other income and expense in our condensed consolidated statements of operation and other comprehensive income.

    We present a non-GAAP adjustment to reclassify the mark-to-market adjustment on the interest rate swap from other income (expense) to net sales to align the swap impact with the impact on customer financing net sales. We believe adjusted net sales, adjusted gross profit and adjusted operating income, which include the gains and losses on the interest rate swap, provides additional comparability from period to period because they present the impact of interest rate fluctuations, net of the mark-to-market swap adjustment, within adjusted net sales. We note the net impact of interest rate fluctuations has a minimal impact on net income.

Management believes that these non-GAAP measures may provide a helpful representation of the company’s performance and enable comparison of financial results between periods where certain items may vary independent of business performance. These non-GAAP financial measures are presented solely for informational and comparative purposes and should not be regarded as a replacement for corresponding, similarly captioned, GAAP measures.

First Quarter Conference Call and Replay

Patterson Companies’ fiscal 2025 first quarter conference call will start at 8:30 a.m. Eastern today. Investors can listen to a live webcast of the conference call at www.pattersoncompanies.com. The conference call will be archived on the Patterson Companies website. A replay of the fiscal 2025 first quarter conference call can be heard for one week at 1-800-770-2030 and by providing the Conference ID 67281 when prompted.

About Patterson Companies Inc.

Patterson Companies Inc. (Nasdaq: PDCO) connects dental and animal health customers in North America and the U.K. to the latest products, technologies, services and innovative business solutions that enable operational and professional success. Our comprehensive portfolio, distribution network and supply chain is equaled only by our dedicated, knowledgeable people who deliver unrivalled expertise and unmatched customer service and support.

Learn more: pattersoncompanies.com

This press release contains, and our officers and representatives may from time to time make, certain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding future financial performance, and the objectives and expectations of management. Forward-looking statements often include words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “seeks” or words of similar meaning, or future or conditional verbs, such as “will,” “should,” “could” or “may.”

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue reliance on any of these forward-looking statements.

Any number of factors could affect our actual results and cause such results to differ materially from those contemplated by any forward-looking statements, including, but not limited to, the following: our dependence on suppliers to manufacture and supply substantially all of the products we sell; potential disruption of distribution capabilities, including service issues with third-party shippers; our dependence on relationships with sales representatives and service technicians to retain customers and develop business; risks of selling private label products, including the risk of adversely affecting our relationships with suppliers; adverse changes in supplier rebates or other purchasing incentives; the risk of technological and market obsolescence for the products we sell; the risk of failing to innovate and develop new and enhanced software and e-services products; our dependence on positive perceptions of Patterson’s reputation; risks associated with illicit human use of pharmaceutical products we distribute; risks inherent in acquiring and disposing of assets or other businesses and risks inherent in integrating acquired businesses; turnover or loss of key personnel or highly skilled employees; risks associated with information systems, software products and cyber-security attacks; risks inherent in our growing use of AI systems to automate processes and analyze data; adverse impacts of wide-spread public health concerns as we experienced with the COVID-19 pandemic and may experience in the future; risks related to climate change; our ability to comply with restrictive covenants and other limits in our credit agreement; the risk that our governing documents and Minnesota law may discourage takeovers and business combinations; the effects of the highly competitive dental and animal health supply markets in which we compete; the effects of consolidation within the dental and animal health supply markets; risks from the formation or expansion of GPOs, provider networks and buying groups that may place us at a competitive disadvantage; exposure to the risks of the animal production business, including changing consumer demand, the cyclical livestock market, weather conditions, the availability of natural resources and other factors outside our control, and the risks of the companion animal business, including the possibility of disease adversely affecting the pet population; exposure to the risks of the health care industry, including changes in demand due to political, economic and regulatory influences and other factors outside our control; increases in over-the-counter sales and e-commerce options; risks of litigation and government inquiries and investigations, including the diversion of management’s attention, the cost of defending against such actions, the possibility of damage awards or settlements, fines or penalties, or equitable remedies (including but not limited to the revocation of or non-renewal of licenses) and inherent uncertainty; failure to comply with health care fraud or other laws and regulations; change and uncertainty in the health care industry; failure to comply with existing or future U.S. or foreign laws and regulations including those governing the distribution of pharmaceuticals and controlled substances; failure to comply with evolving data privacy laws and regulations; tax legislation; risks inherent in international operations, including currency fluctuations; and uncertain macro-economic conditions, including inflationary pressures.

The order in which these factors appear should not be construed to indicate their relative importance or priority. We caution that these factors may not be exhaustive, accordingly, any forward-looking statements contained herein should not be relied upon as a prediction of actual results.

You should carefully consider these and other relevant factors, including those risk factors in Part I, Item 1A, (“Risk Factors”) in our most recent Form 10-K and information which may be contained in our other filings with the U.S. Securities and Exchange Commission, or SEC, when reviewing any forward-looking statement.

Investors should understand it is impossible to predict or identify all such factors or risks. As such, you should not consider the foregoing list, or the risks identified in our SEC filings, to be a complete discussion of all potential risks or uncertainties.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We do not undertake any obligation to release publicly any revisions to any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

 

PATTERSON COMPANIES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

(Unaudited)

 

 

Three Months Ended

 

July 27, 2024

 

July 29, 2023

 

 

 

 

Net sales

$

1,541,742

 

 

$

1,576,745

 

 

 

 

 

Gross profit

 

312,609

 

 

 

319,055

 

 

 

 

 

Operating expenses

 

283,240

 

 

 

280,833

 

 

 

 

 

Operating income

 

29,369

 

 

 

38,222

 

 

 

 

 

Other income (expense):

 

 

 

Other income, net

 

1,714

 

 

 

11,901

 

Interest expense

 

(13,223

)

 

 

(9,512

)

 

 

 

 

Income before taxes

 

17,860

 

 

 

40,611

 

 

 

 

 

Income tax expense

 

4,221

 

 

 

9,481

 

 

 

 

 

Net income

 

13,639

 

 

 

31,130

 

Net loss attributable to noncontrolling interests

 

(76

)

 

 

(104

)

Net income attributable to Patterson Companies, Inc.

$

13,715

 

 

$

31,234

 

 

 

 

 

Earnings per share attributable to Patterson Companies, Inc.:

 

 

 

Basic

$

0.16

 

 

$

0.33

 

Diluted

$

0.15

 

 

$

0.32

 

 

 

 

 

Weighted average shares:

 

 

 

Basic

 

88,127

 

 

 

95,544

 

Diluted

 

88,645

 

 

 

96,190

 

 

 

 

 

Dividends declared per common share

$

0.26

 

 

$

0.26

 

 

PATTERSON COMPANIES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

(Unaudited)

 

 

July 27, 2024

 

April 27, 2024

 

 

 

 

ASSETS

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

148,079

 

$

114,462

Receivables, net

 

442,342

 

 

547,287

Inventory, net

 

849,504

 

 

782,898

Prepaid expenses and other current assets

 

322,185

 

 

334,116

Total current assets

 

1,762,110

 

 

1,778,763

Property and equipment, net

 

226,151

 

 

229,081

Operating lease right-of-use assets, net

 

124,473

 

 

122,295

Goodwill and identifiable intangibles, net

 

340,166

 

 

349,589

Investments

 

167,386

 

 

166,320

Long-term receivables, net and other

 

254,472

 

 

250,684

Total assets

$

2,874,758

 

$

2,896,732

 

 

 

 

LIABILITIES AND STOCKHOLDERS' EQUITY

 

 

 

Current liabilities:

 

 

 

Accounts payable

$

656,977

 

$

745,375

Other accrued liabilities

 

223,025

 

 

245,610

Operating lease liabilities

 

33,643

 

 

32,815

Current maturities of long-term debt

 

123,875

 

 

122,750

Borrowings on revolving credit

 

320,000

 

 

186,000

Total current liabilities

 

1,357,520

 

 

1,332,550

Long-term debt

 

327,153

 

 

328,911

Non-current operating lease liabilities

 

94,261

 

 

92,464

Other non-current liabilities

 

143,323

 

 

141,075

Total liabilities

 

1,922,257

 

 

1,895,000

Stockholders' equity

 

952,501

 

 

1,001,732

Total liabilities and stockholders' equity

$

2,874,758

 

$

2,896,732

 

PATTERSON COMPANIES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

 

 

Three Months Ended

 

July 27, 2024

 

July 29, 2023

 

 

 

 

Operating activities:

 

 

 

Net income

$

13,639

 

 

$

31,130

 

Adjustments to reconcile net income to net cash used in operating activities:

 

 

 

Depreciation and amortization

 

22,750

 

 

 

21,033

 

Stock-based compensation

 

8,060

 

 

 

7,015

 

Non-cash losses (gains) and other, net

 

1,745

 

 

 

2,268

 

Change in assets and liabilities:

 

 

 

Receivables

 

(140,656

)

 

 

(154,602

)

Inventory

 

(65,292

)

 

 

(114,323

)

Accounts payable

 

(91,995

)

 

 

(11,093

)

Accrued liabilities

 

(22,698

)

 

 

(21,715

)

Other changes from operating activities, net

 

(10,523

)

 

 

(13,079

)

Net cash used in operating activities

 

(284,970

)

 

 

(253,366

)

Investing activities:

 

 

 

Additions to property and equipment and software

 

(13,507

)

 

 

(17,087

)

Collection of deferred purchase price receivables

 

271,834

 

 

 

242,013

 

Payments related to acquisitions, net of cash acquired

 

 

 

 

(1,108

)

Net cash provided by investing activities

 

258,327

 

 

 

223,818

 

Financing activities:

 

 

 

Dividends paid

 

(23,312

)

 

 

(25,432

)

Repurchases of common stock

 

(50,000

)

 

 

(29,508

)

Payments on long-term debt

 

(750

)

 

 

(750

)

Draw on revolving credit

 

134,000

 

 

 

31,000

 

Other financing activities

 

(1,151

)

 

 

1,574

 

Net cash provided by (used in) financing activities

 

58,787

 

 

 

(23,116

)

Effect of exchange rate changes on cash

 

1,473

 

 

 

1,568

 

Net change in cash and cash equivalents

 

33,617

 

 

 

(51,096

)

Cash and cash equivalents at beginning of period

 

114,462

 

 

 

159,669

 

Cash and cash equivalents at end of period

$

148,079

 

 

$

108,573

 

 

PATTERSON COMPANIES, INC.

SALES SUMMARY

(Dollars in thousands)

(Unaudited)

 

 

July 27, 2024

 

July 29, 2023

 

Total

Sales

Growth

 

Foreign

Exchange

Impact

 

Net Interest Rate Swap

 

Internal Sales

Growth

Three Months Ended

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Consolidated net sales

 

 

 

 

 

 

 

 

 

 

 

Consumable

$

1,278,413

 

$

1,315,725

 

 

(2.8

)%

 

%

 

%

 

(2.8

)%

Equipment

 

159,286

 

 

163,971

 

 

(2.9

)

 

(0.2

)

 

 

 

(2.7

)

Value-added services and other

 

104,043

 

 

97,049

 

 

7.2

 

 

(0.1

)

 

10.7

 

 

(3.4

)

Total

$

1,541,742

 

$

1,576,745

 

 

(2.2

)%

 

(0.1

)%

 

0.7

%

 

(2.8

)%

 

 

 

 

 

 

 

 

 

 

 

 

Dental

 

 

 

 

 

 

 

 

 

 

 

Consumable

$

344,117

 

$

352,047

 

 

(2.3

)%

 

(0.2

)%

 

%

 

(2.1

)%

Equipment

 

133,858

 

 

137,549

 

 

(2.7

)

 

(0.3

)

 

 

 

(2.4

)

Value-added services and other

 

72,382

 

 

77,704

 

 

(6.8

)

 

(0.1

)

 

 

 

(6.7

)

Total

$

550,357

 

$

567,300

 

 

(3.0

)%

 

(0.2

)%

 

%

 

(2.8

)%

 

 

 

 

 

 

 

 

 

 

 

 

Animal Health

 

 

 

 

 

 

 

 

 

 

 

Consumable

$

934,296

 

$

963,678

 

 

(3.0

)%

 

%

 

%

 

(3.0

)%

Equipment

 

25,428

 

 

26,422

 

 

(3.8

)

 

 

 

 

 

(3.8

)

Value-added services and other

 

22,689

 

 

20,890

 

 

8.6

 

 

0.3

 

 

 

 

8.3

 

Total

$

982,413

 

$

1,010,990

 

 

(2.8

)%

 

%

 

%

 

(2.8

)%

 

 

 

 

 

 

 

 

 

 

 

 

Corporate

 

 

 

 

 

 

 

 

 

 

 

Value-added services and other

$

8,972

 

$

(1,545

)

 

n/m

 

 

%

 

n/m

 

 

(0.2

)%

Total

$

8,972

 

$

(1,545

)

 

n/m

 

 

%

 

n/m

 

 

(0.2

)%

 

PATTERSON COMPANIES, INC.

OPERATING INCOME BY SEGMENT

(In thousands)

(Unaudited)

 

 

Three Months Ended

 

July 27, 2024

 

July 29, 2023

 

 

 

 

Operating income (loss)

 

 

 

Dental

$

27,058

 

 

$

38,670

 

Animal Health

 

25,367

 

 

 

29,693

 

Corporate

 

(23,056

)

 

 

(30,141

)

Total

$

29,369

 

 

$

38,222

 

 

PATTERSON COMPANIES, INC.

RECONCILIATION OF GAAP TO NON-GAAP MEASURES

(Dollars in thousands, except per share amounts)

(Unaudited)

 

For the three months ended July 27, 2024

 

GAAP

 

Deal amortization

 

Interest rate swap

 

Non-GAAP

Net sales

 

$

1,541,742

 

 

$

 

 

$

(3,755

)

 

$

1,537,987

 

Gross profit

 

 

312,609

 

 

 

 

 

 

(3,755

)

 

 

308,854

 

Operating expenses

 

 

283,240

 

 

 

(9,639

)

 

 

 

 

 

273,601

 

Operating income

 

 

29,369

 

 

 

9,639

 

 

 

(3,755

)

 

 

35,253

 

Other income (expense), net

 

 

(11,509

)

 

 

 

 

 

3,755

 

 

 

(7,754

)

Income before taxes

 

 

17,860

 

 

 

9,639

 

 

 

 

 

 

27,499

 

Income tax expense

 

 

4,221

 

 

 

2,305

 

 

 

 

 

 

6,526

 

Net income

 

 

13,639

 

 

 

7,334

 

 

 

 

 

 

20,973

 

Net loss attributable to noncontrolling interests

 

 

(76

)

 

 

 

 

 

 

 

 

(76

)

Net income attributable to Patterson Companies, Inc.

 

$

13,715

 

 

$

7,334

 

 

$

 

 

$

21,049

 

 

 

 

 

 

 

 

 

 

Diluted earnings per share attributable to Patterson Companies, Inc.*

 

$

0.15

 

 

$

0.08

 

 

$

 

 

$

0.24

 

 

 

 

 

 

 

 

 

 

Gross margin

 

 

20.3

%

 

 

 

 

 

 

20.1

%

Operating margin

 

 

1.9

%

 

 

 

 

 

 

2.3

%

Effective tax rate

 

 

23.6

%

 

 

 

 

 

 

23.7

%

 

 

 

 

 

 

 

 

 

For the three months ended July 29, 2023

 

GAAP

 

Deal amortization

 

Interest rate swap

 

Non-GAAP

Net sales

 

$

1,576,745

 

 

$

 

 

$

6,775

 

 

$

1,583,520

 

Gross profit

 

 

319,055

 

 

 

 

 

 

6,775

 

 

 

325,830

 

Operating expenses

 

 

280,833

 

 

 

(9,626

)

 

 

 

 

 

271,207

 

Operating income

 

 

38,222

 

 

 

9,626

 

 

 

6,775

 

 

 

54,623

 

Other income (expense), net

 

 

2,389

 

 

 

 

 

 

(6,775

)

 

 

(4,386

)

Income before taxes

 

 

40,611

 

 

 

9,626

 

 

 

 

 

 

50,237

 

Income tax expense

 

 

9,481

 

 

 

2,304

 

 

 

 

 

 

11,785

 

Net income

 

 

31,130

 

 

 

7,322

 

 

 

 

 

 

38,452

 

Net loss attributable to noncontrolling interests

 

 

(104

)

 

 

 

 

 

 

 

 

(104

)

Net income attributable to Patterson Companies, Inc.

 

$

31,234

 

 

$

7,322

 

 

$

 

 

$

38,556

 

 

 

 

 

 

 

 

 

 

Diluted earnings per share attributable to Patterson Companies, Inc.*

 

$

0.32

 

 

$

0.08

 

 

$

 

 

$

0.40

 

 

 

 

 

 

 

 

 

 

Gross margin

 

 

20.2

%

 

 

 

 

 

 

20.6

%

Operating margin

 

 

2.4

%

 

 

 

 

 

 

3.4

%

Effective tax rate

 

 

23.3

%

 

 

 

 

 

 

23.5

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

* May not sum due to rounding

 

 

 

 

 

 

 

 

 

PATTERSON COMPANIES, INC.

FREE CASH FLOW

(In thousands)

(Unaudited)

 

 

Three Months Ended

 

July 27, 2024

 

July 29, 2023

Net cash used in operating activities

$

(284,970

)

 

$

(253,366

)

Additions to property and equipment and software

 

(13,507

)

 

 

(17,087

)

Collection of deferred purchase price receivables

 

271,834

 

 

 

242,013

 

Free cash flow

$

(26,643

)

 

$

(28,440

)

 

INVESTOR CONTACT: John M. Wright, Investor Relations

TEL: 651.686.1364

EMAIL: investor.relations@pattersoncompanies.com



MEDIA CONTACT: Patterson Corporate Communications

TEL: 651.905.3349

EMAIL: corporate.communications@pattersoncompanies.com



WEB: pattersoncompanies.com

Source: Patterson Companies, Inc.

FAQ

What were Patterson Companies' (PDCO) Q1 fiscal 2025 earnings per share?

Patterson Companies reported GAAP earnings of $0.15 per diluted share and adjusted earnings of $0.24 per diluted share for Q1 fiscal 2025.

How did the cybersecurity attack on Change Healthcare affect Patterson Companies (PDCO)?

The cybersecurity attack on Change Healthcare negatively impacted Patterson's dental segment, particularly in the value-added services category, contributing to lower sales and operating margins.

What is Patterson Companies' (PDCO) fiscal 2025 earnings guidance?

Patterson Companies reaffirmed its fiscal 2025 guidance, expecting GAAP earnings of $2.00 to $2.10 per diluted share and adjusted earnings of $2.33 to $2.43 per diluted share.

How much did Patterson Companies (PDCO) return to shareholders in Q1 fiscal 2025?

Patterson Companies returned $73.3 million to shareholders through dividends and share repurchases in the first quarter of fiscal 2025.

Patterson Companies, Inc.

NASDAQ:PDCO

PDCO Rankings

PDCO Latest News

PDCO Stock Data

1.78B
87.13M
1.08%
90.27%
3.81%
Medical Distribution
Wholesale-medical, Dental & Hospital Equipment & Supplies
Link
United States of America
ST PAUL